Pura Vida Investments LLC Sells 44,940 Shares of Establishment Labs Holdings Inc. $ESTA

Pura Vida Investments LLC lowered its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 50.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,000 shares of the company’s stock after selling 44,940 shares during the period. Establishment Labs comprises 11.9% of Pura Vida Investments LLC’s portfolio, making the stock its 4th largest holding. Pura Vida Investments LLC owned approximately 0.15% of Establishment Labs worth $1,845,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of ESTA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after purchasing an additional 9,557 shares during the last quarter. Milestone Asset Management LLC purchased a new stake in Establishment Labs in the 2nd quarter valued at approximately $523,000. Tyro Capital Management LLC grew its holdings in Establishment Labs by 0.3% during the 2nd quarter. Tyro Capital Management LLC now owns 1,066,721 shares of the company’s stock valued at $45,560,000 after buying an additional 2,835 shares during the last quarter. Geode Capital Management LLC grew its holdings in Establishment Labs by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after buying an additional 299 shares during the last quarter. Finally, Garnet Equity Capital Holdings Inc. purchased a new position in Establishment Labs during the second quarter worth $7,062,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their price objective on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Citigroup upped their target price on shares of Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Stephens lifted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. BTIG Research boosted their price objective on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.00.

Establishment Labs Stock Up 0.0%

ESTA opened at $71.14 on Thursday. Establishment Labs Holdings Inc. has a 12 month low of $26.56 and a 12 month high of $83.31. The business has a 50-day moving average of $71.10 and a two-hundred day moving average of $59.22. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.10. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -40.88 and a beta of 0.91.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The business had revenue of $64.62 million for the quarter, compared to analysts’ expectations of $63.80 million. During the same period last year, the company earned ($1.19) earnings per share. The company’s quarterly revenue was up 45.2% on a year-over-year basis. On average, research analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.